已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Balancing the Therapeutic Ratio in DLBCL Requires Appropriate, Individualized Patient Selection Rather Than Broad Elimination of Radiation Therapy

医学 美罗华 合并(业务) 临床终点 淋巴瘤 疾病 放射治疗 重症监护医学 肿瘤科 临床试验 医学物理学 内科学 业务 会计
作者
Belinda A. Campbell,Richard L. Bakst,Sarah A. Milgrom,John F. Seymour
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:113 (3): 479-488 被引量:5
标识
DOI:10.1016/j.ijrobp.2022.02.017
摘要

The potential additional benefit of consolidation radiation therapy (RT) for diffuse large B-cell lymphoma (DLBCL) has been hotly debated for decades. The addition of consolidation RT unequivocally reduces the risk of local failure; however, the more challenging question has been whether this local control benefit ultimately translates into an overall survival advantage. Now firmly within the rituximab and positron emission tomography (PET) era, this question has become even more contentious and at times divisive. Recent studies have focused on strategizing management approaches to enable the selective omission of consolidation RT, citing the desire to avoid the risk of RT-induced toxicities as the primary driver for these strategies. However, this localized toxicity profile must be considered and counterbalanced against the risks of disease relapse, in particular the greater morbidity and higher economic costs associated with current and emerging salvage options for those patients with relapsed disease. Herein, we review a selection of the most impactful papers from the recent published literature of consolidation RT for DLBCL in the rituximab and PET eras (Table 1), discuss our perspective on the roles of consolidation RT in current clinical practice, and focus on the importance of patient selection to identify those in whom improved local control has the potential to achieve optimal patient outcomes. TABLE 1Summary of the three recently published and impactful studies of consolidation RT for DLBCL in the era of PET and rituximab Study Eligibility Study design Treatment groups Primary endpoint Other notable findings LYSA/GOELAMS trial 02-03(1) PET-staged stage I or limited Stage II, and non-bulky (<7cm) DLBCL, age 18-75 years Prospective, Phase 3, randomized, non-inferiority study (upper limit of 8%) All patients received 4 cycles of R-CHOP-14 followed by a PET scan.Randomized to: (a) RT: 40Gy/20# consolidation IFRT,(b) No RT.For patients who did not achieve CMR after cycle 4: 2 additional cycles of R-CHOP+RT were delivered (both study arms). 5-year EFS: R-CHOP alone was not inferior to R-CHOP + RT (89% vs 92%, HR 0.61 CI, 0.3-1.2; P = 0.18). 5-year OS: not statistically different for R-CHOP alone vs R-CHOP + RT (92% vs 96%, HR 0.62; 95% CI, 0.3-1.5; P = 0.28). No local failures after RT.Severe acute toxicities were less common from RT than R-CHOP. National Clinical Trials Network study S1001(13) PET-staged stage I or II non-bulky (<10cm) high grade B-cell lymphoma. Prospective, Phase 2, non-randomized study All patients received 3 cycles of R-CHOP followed by iPET:(a) iPET-negative: 1 additional cycle of R-CHOP,(b) iPET-positive: IFRT plus ibritumomab tiuxetan and rituximab. 5-year PFS: similar for iPET-negative and iPET-positive (89% vs 86%). 5-year OS: similar outcomes for iPET-negative and iPET positive (91% vs 85%).No local failures after RT.No severe RT toxicities reported. BC Cancer retrospective study(16) Non-PET staged, advanced DLBCL: stage III/IV or stages I/II with B symptoms and/or bulky disease (≥10cm). Retrospective analysis of a protocol-driven, population-based treatment strategy. All patients received ≥6 cycles of R-CHOP, and EOT PET:(a) PET-negative: no further treatment,(b) PET-positive: considered. for consolidation ISRT (received by 53%) 3-year TTP: favored the PET-negative group, 83% vs 56% for PET-positive (p<0.001). 3-year OS: favored the PET-negative group, 87% vs 64% for PET-positive (p<0.001).PET-positive patients who received RT had similar outcomes to PET-negative patients, but poorer outcomes were observed for PET-positive patients who did not receive RT (3-year OS, 80% vs 87% vs 44%, respectively).No toxicity data reported. Abbreviations: CI = confidence interval; CMR = complete metabolic response; DLBCL = diffuse large B-cell lymphoma; EFS = event-free survival; EOT PET = end of treatment PET; HR = hazard ratio; IFRT = involved field RT; iPET = interim PET; ISRT = involved site RT; LYSA/GOELAMS = Lymphoma Study Association/Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang; OS = overall survival; PET = positron emission tomography; PFS = progression-free survival; RT = radiation therapy; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; TTP = time to progression. Open table in a new tab Abbreviations: CI = confidence interval; CMR = complete metabolic response; DLBCL = diffuse large B-cell lymphoma; EFS = event-free survival; EOT PET = end of treatment PET; HR = hazard ratio; IFRT = involved field RT; iPET = interim PET; ISRT = involved site RT; LYSA/GOELAMS = Lymphoma Study Association/Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang; OS = overall survival; PET = positron emission tomography; PFS = progression-free survival; RT = radiation therapy; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; TTP = time to progression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
5秒前
兽王打的面包完成签到,获得积分20
5秒前
10秒前
dbq完成签到 ,获得积分10
10秒前
乐羽乐完成签到,获得积分10
10秒前
zzzzzz完成签到 ,获得积分10
10秒前
第二支羽毛完成签到,获得积分10
12秒前
个性乐儿完成签到,获得积分10
12秒前
顾矜的应助被nnn采纳,获得10
13秒前
小田完成签到 ,获得积分10
14秒前
秋风的应助被yang采纳,获得10
14秒前
leotao完成签到,获得积分10
14秒前
14秒前
田様的应助被再吃亿大口采纳,获得10
15秒前
jianglai发布了新的文献求助200
15秒前
qq发布了新的文献求助10
15秒前
AdamJie发布了新的文献求助30
17秒前
MX完成签到 ,获得积分10
17秒前
成就马里奥完成签到,获得积分10
17秒前
17秒前
香蕉觅云的应助被Phoebe采纳,获得10
18秒前
嘻嘻哈哈的应助被谨慎的寄云采纳,获得10
18秒前
19秒前
浪迹发布了新的文献求助30
19秒前
深情安青的应助被英俊h采纳,获得10
20秒前
llx666完成签到,获得积分10
21秒前
chiaoyin999发布了新的文献求助10
21秒前
Pia完成签到 ,获得积分10
22秒前
bm发布了新的文献求助10
22秒前
22秒前
24秒前
小鱼发布了新的文献求助10
24秒前
平常的人雄完成签到,获得积分10
25秒前
25秒前
25秒前
Drwang完成签到,获得积分10
26秒前
火山口发布了新的文献求助10
26秒前
26秒前
时间完成签到,获得积分10
27秒前
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184867
求助须知:如何正确求助?哪些是违规求助? 9573803
关于积分的说明 21833148
捐赠科研通 7782177
什么是DOI,文献DOI怎么找? 3434414
关于科研通互助平台的介绍 2558563
邀请新用户注册赠送积分活动 2481067